Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: Enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models

Vaccine

Volumn 18, Issue 7-8, 1999, Pages 623-632

  Dégano, Pilar ^a,b   Schneider, Jörg ^b   Hannan, Carolyn M ^b   Gilbert, Sarah C ^c   Hill, Adrian V S ^b,c  

^a PowderJect Pharmaceuticals plc   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

CTL; Rodent; Vaccination

Indexed keywords

DNA VACCINE; PLASMID DNA; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; GENE GUN; IMMUNOGENICITY; INFLUENZA; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MALARIA; MALE; MOUSE; NONHUMAN; PLASMODIUM BERGHEI; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VACCINIA VIRUS;

ANIMALS; BIOLISTICS; CD8-POSITIVE T-LYMPHOCYTES; DNA, PROTOZOAN; DNA, VIRAL; FEMALE; IMMUNIZATION, SECONDARY; INFLUENZA VACCINES; MALARIA; MALARIA VACCINES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PLASMODIUM BERGHEI; VACCINES, ATTENUATED; VACCINES, DNA; VACCINIA VIRUS;

EID: 0344994574     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00278-9     Document Type: Article

References (46)

1. Tsui L.V., Guidotti L.G., Ishikawa T., Chisari F.V. Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc Natl Acad Sci USA. 92:1995;12398-12402.
2. Guidotti L.G., Ishikawa T., Hobbs M.V., Matzke B., Schreiber R., Chisari F.V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 4:1996;25-36.
3. Tighe H., Corr M., Roman M., Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol Today. 19:1998;89-97.
4. Bennink J.R., Yewdell J.W., Smith G.L., Moller C., Moss B. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature. 311:1984;578-579.
5. Bender B.S., Rowe C.A., Taylor S.F., Wyatt L.S., Moss B., Small P.A. Jr. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol. 70:1996;6418-6424.
6. Thomson S.A., Elliot S.L., Sherritt M.A., Sproat K.W., Coupar B.E.H., Scalzo A.A., Forbes C.A., Ladhams A.M., Mo X.Y., Tripp R.A., Doherty P.C., Moss D.J., Suhrbier A. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol. 157:1996;822-826.
7. An L.L., Pamer E., Whitton J.L. A recombinant minigene vaccine containing a nonameric cytotoxic-T-lymphocyte epitope confers limited protection against Listeria monocytogenes infection. Infect Immun. 64:1996;1685-1693.
8. Stickl H., Hochstein-Mintzel V. Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus ("MVA virus"). Munch Med Wochenschr. 113:1971;1149-1153.
9. Mayr A., Stickl H., Muller H.K., Danner K., Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. Zentralbl Bakteriol B. 167:1978;375-390.
10. Sutter G., Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA. 89:1992;10847-10851.
11. Eisenbraun M.D., Fuller D.H., Haynes J.R. Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. DNA Cell Biol. 12:1993;791-797.
12. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci USA. 90:1993;11478-11482.
13. Pertmer T.M., Eisenbraun M.D., McCabe D., Prayaga S.K., Fuller D.H., Haynes J.R. Gene gun based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine. 13:1995;1427-1430.
14. Dégano P., Sarphie D.F., Bangham C.R.M. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect® system. Vaccine. 16:1998;394-398.
15. Mackenzie C.D., Taylor P.M., Askonas B.A. Rapid recovery of lung histology correlates with clearance of influenza virus by specific CD8+ cytotoxic T cells. Immunology. 67:1989;375-381.
16. Taylor P.M., Askonas B.A. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology. 58:1986;417-420.
17. Rodrigues M.M., Cordey A.S., Arreaza G., Corradin G., Romero P., Maryanski J.L., Nussenzweig R.S., Zavala F. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol. 3:1991;579-585.
18. Romero P., Maryanski J.L., Corradin G., Nussenzweig R.S., Nussenzweig V., Zavala F. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature. 341:1989;323-325.
19. White K.L., Snyder H.L., Krzych U. MHC class I dependent presentation of exoerythrocytic antigens to CD8+ T lymphocytes is required for protective immunity against Plasmodium berghei. J Immunol. 156:1996;3374-3381.
20. Doolan D.L., Sedegah M., Hedstrom R.C., Hobart P., Charoenvit Y., Hoffman S.L. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity. J Exp Med. 183:1996;1739-1746.
21. Sedegah M., Hedstrom R., Hobart P., Hoffman S.L. Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. Proc Natl Acad Sci USA. 91:1994;9866-9870.
22. Doolan D.L., Hoffmann S.L. Multi-gene vaccination against malaria: a multi-stage, multi-immune response approach. Parasitol Today. 13:1997;171-178.
23. Schneider J., Gilbert S.C., Blanchard T.J., Hanke T., Robson K.J., Hannan C.M., Becker M., Sinden R., Smith G.L., Hill A.V.S. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med. 4:1998;397-402.
24. Sedegah M., Jones T.R., Kaur M., Hedstrom R., Hobart P., Tine J.A., Hoffman S.L. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA. 95:1998;7648-7653.
25. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., Gromkowski S.H., Deck R.R., DeWitt C.M., Friedman A., Hawe L.A., Leander K.R., Martinez D., Perry H.C., Shiver J.W., Montgomery D.L., Liu M.A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1993;1745-1749.
26. Montgomery D.L., Shiver J.W., Leander K.R., Perry H.C., Friedman A., Martinez D., Ulmer J.B., Donnelly J.J., Liu M.A. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol. 12:1993;777-783.
27. Stitz L., Schmitz C., Binder D., Zinkernagel R., Paoletti E., Becht H. Characterization and immunological properties of influenza A virus nucleoprotein (NP): cell-associated NP isolated from infected cells or viral NP expressed by vaccinia recombinant virus do not confer protection. J Gen Virol. 71:1990;1169-1179.
28. Lawson C.M., Bennink J.R., Restifo N.P., Yewdell J.W., Murphy B.R. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge. J Virol. 68:1994;3505-3511.
29. Hanke T., Schneider J., Gilbert S.C., Hill A.V.S., McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine. 16:1998;426-435.
30. Gilbert S.C., Plebanski M., Harris S.J., Allsopp C.E.M., Thomas R., Layton G.T., Hill A.V.S. A protein particle vaccine containing multiple malaria epitopes. Nature Biotechnol. 15:1997;1280-1284.
31. Mackett M., Smith G.L., Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol. 49:1984;857-864.
32. Carroll M.W., Moss B. E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses. Biotechniques. 19:1995;352-356.
33. Bodmer H.C., Pemberton R.M., Rothbard J.B., Askonas B.A. Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein. Cell. 52:1988;253-258.
34. Rodrigues M., Li S., Murata K., Rodríguez D., Rodríguez J.R., Bacik I., Bennink J.R., Yewdell J.W., García-Sastre A., Nussenzweig R.S., Esteban M., Palese P., Zavala F. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes: comparison of their immunogenicity and capacity to induce protective immunity. J Immunol. 153:1994;4636-4648.
35. Plebanski M., Gilbert S.C., Schneider J., Hannan C.M., Layton G., Blanchard T., Becker M., Smith G., Butcher G., Sinden R.E., Hill A.V.S. Protection from Plasmodium berghei infection by priming and boosting T cells to a single class-I restricted epitope with recombinant carriers suitable for human use. Eur J Immunol. 28:1998;4345-4355.
36. Ulmer J.B., Fu T.M., Deck R.R., Friedman A., Guan L., DeWitt C., Liu X., Wang S., Liu M.A., Donnelly J.J., Caulfield M.J. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol. 72:1998;5648-5653.
37. Raz E., Carson D.A., Parker S.E., Parr T.B., Abai A.M., Aichinger G., Gromkowski S.H., Singh M., Lew D., Yankauckas M.A., Baird S.M., Rhodes G.H. Intradermal gene immunization: the possible role of DNA uptake in the induction of cellular immunity to viruses. Proc Natl Acad Sci USA. 91:1994;9519-9523.
38. Robinson H.L., Boyle C.A., Feltquate D.M., Morin M.J., Santoro J.C., Webster R.G. DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs. J Infect Dis. 176:1997;S50-S55.
39. Pertmer T.M., Roberts T.R., Haynes J.R. Influenza virus nucleoprotein-specific immunoglobulin G suclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J Virol. 70:1996;6119-6125.
40. Graham M.B., Braciale V.L., Braciale T.J. Influenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection. J Exp Med. 180:1994;1273-1282.
41. Leitner W.W., Seguin M.C., Ballou W.R., Seitz J.P., Schultz A.M., Sheehy M.J., Lyon J.A. Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. J Immunol. 159:1997;6112-6119.
42. Satchidanandam V., Zavala F., Moss B. Studies using a recombinant vaccinia virus expressing the circumsporozoite protein of Plasmodium berghei. Mol Biochem Parasitol. 48:1991;89-100.
43. Li S., Rodrigues M., Rodríguez D., Rodríguez J.R., Esteban M., Palese P., Nussenzweig R.S., Zavala F. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA. 90:1993;5214-5218.
44. Lanar D.E., Tine J.A., de Taisne C., Seguin M.C., Cox W.I., Winslow J.P., Ware L.A., Kauffman E.B., Gordon D., Ballou W.R., Paoletti E., Sadoff J.C. Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria. Infect Immun. 64:1996;1666-1671.
45. Hanke T., Blanchard T.J., Schneider J., Ogg G.S., Tan R., Becker M., Gilbert S.C., Hill A.V.S., Smith G.L., McMichael A. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J Gen Virol. 79:1998;83-90.
46. Calarota S., Bratt G., Nordlund S., Hinkula J., Leandersson A.C., Sandström E., andWahren B. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet. 351:1998;1320-1325.